Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis: A Randomized Clinical Trial

By sjmartinez • August 22, 2024

Armstrong AW, Gooderham M, Lynde C, Maari C, Forman S, Green L, Laquer V, Zhang X, Franchimont N, Gangolli EA, Blau J, Zhao Y, Zhang W, Srivastava B, Heap G, Papp K. Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis: A Randomized Clinical Trial. JAMA Dermatol. 2024 Aug 21:e242701. doi: 10.1001/jamadermatol.2024.2701. Epub ahead of print. PMID: 39167366; PMCID: PMC11339701.

Tags: Dermatology, Publications

Patient-Identified Treatment Goals for Psoriatic Disease: Results From a US Patient Survey

Armstrong A, Levit NA, Schneider B, Seiden R, Shi L, Kaplan B, Wu JJ. Patient-Identified Treatment Goals for Psoriatic Disease: Results From a US Patient[...]

A genomic analysis reveals the diversity of cellulosome displaying bacteria

Minor CM, Takayesu A, Ha SM, Salwinski L, Sawaya MR, Pellegrini M, Clubb RT. A genomic analysis reveals the diversity of cellulosome displaying bacteria. Front[...]

PD-1 blockade plus cisplatin-based chemotherapy in patients with small cell/neuroendocrine bladder and prostate cancers

Gu Y, Ly A, Rodriguez S, Zhang H, Kim J, Mao Z, Sachdeva A, Zomorodian N, Pellegrini M, Li G, Liu S, Drakaki A, Rettig[...]